Preparation and evaluation of anticancer drug loaded acronycine nanoparticulate formulation

Abstract

The first line of defence against many cancer types is chemotherapy, which is frequently associated with serious side effects. Plant extracts may have anticancer properties. Ursolic acid is one of many signalling pathways in the cancer cell that can be modified by triterpenoids; however they are hydrophobic and have a low bioavailability. Tamoxifen slows the growth of cancer cells by selectively blocking oestrogen receptors, however it carries a substantial and even fatal risk of blood clots, stroke, subsequent endometrial cancer, and thromboembolic events. Drug-loaded nanoparticulate formulations are the answer to the aforementioned issue. The most effective material for encasing a range of medications has frequently been suggested as a combination of polymers and lipids. In the present work, two different nanoformulations were prepared namely, Acronine loaded Eudragit-E nanoparticles (AENPs), Acronine co-delivered Tamoxifen Chitosan gum nanoparticles (ATCNPs). newline